EMA’s CHMP grants PRIME status to AbelZeta’s C-CAR168
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has granted priority medicines (PRIME) designation to AbelZeta…
All articles by Salong Debbarma
Salong Debbarma
-
-
Halozyme and Incyte sign licence agreement for INCA033989 formulations
Halozyme Therapeutics has signed a global partnership and licence agreement with Incyte to assess additional subcutaneous formulations of INCA033989, a…
-
Samsung Biologics to acquire PolyPeptide in $1.81bn cash deal
Samsung Biologics is set to acquire PolyPeptide Group through an all-cash public tender offer valued at SFr1.46bn ($1.81bn). The proposed…
-
Aptar unveils framework for injectable drug delivery systems
Aptar Pharma has launched a collaborative system-level framework designed to support the development of injectable drug delivery systems. The framework…
-
FDA grants traditional approval to Novartis’ Fabhalta for IgAN
The US Food and Drug Administration (FDA) has issued traditional approval to Novartis for Fabhalta (iptacopan), to slow the decline…
-
JCVI issues recommendation on adolescent MenB vaccination in UK
The UK’s Joint Committee on Vaccination and Immunisation (JCVI) has recommended a routine programme with the 4CMenB vaccine for adolescents.…
-
Telix opens radiopharmaceutical facility in Australia for cancer treatment
Telix Pharmaceuticals has officially opened a radiopharmaceutical research, manufacturing, and treatment facility in Melbourne, Australia, to expedite the delivery of…
-
Harbour BioMed and Kelun-Biotech receive China IND approval for asthma therapy
Harbour BioMed and Kelun-Biotech have received approval from China’s National Medical Products Administration (NMPA) for their investigational new drug (IND)…
-
FDA grants priority review to Roche’s Gazyva/Gazyvaro for pMN
The US Food and Drug Administration (FDA) has granted priority review to Roche’s supplemental biologics licence application (sBLA) for Gazyva/Gazyvaro…
-
Innovent licenses IBI355 rights to Spero for up to $1.1bn
Innovent Biologics has agreed an exclusive licence deal worth up to $1.1bn with Spero Therapeutics, granting Spero the rights to…